1. Home
  2. VYLR vs NTRA Comparison

VYLR vs NTRA Comparison

Compare VYLR & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VYLR

Vylor Inc. Common Stock

N/A

Current Price

$74.39

Market Cap

52.2B

ML Signal

N/A

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$402.25

Market Cap

56.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VYLR
NTRA
Founded
1802
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Medical Specialities
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.2B
56.7B
IPO Year
2026
2015

Fundamental Metrics

Financial Performance
Metric
VYLR
NTRA
Price
$74.39
$402.25
Analyst Decision
Buy
Strong Buy
Analyst Count
16
23
Target Price
$82.07
★ $403.89
AVG Volume (30 Days)
★ 4.7M
1.5M
Earning Date
11-11-2026
11-05-2026
Dividend Yield
★ 1.01%
N/A
EPS Growth
N/A
★ 0.65
EPS
★ N/A
N/A
Revenue
N/A
★ $210,939,000.00
Revenue This Year
N/A
$26.19
Revenue Next Year
$3.56
$20.84
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$65.11
$181.00
52 Week High
$77.39
$437.41

Technical Indicators

Market Signals
Indicator
VYLR
NTRA
Relative Strength Index (RSI) 65.51 56.53
Support Level $71.20 $380.39
Resistance Level $76.13 $437.41
Average True Range (ATR) 2.80 18.93
MACD -0.12 -2.67
Stochastic Oscillator 56.55 39.34

Price Performance

Historical Comparison
VYLR
NTRA

About VYLR Vylor Inc. Common Stock

Vylor is a seed and crop genetics pure-play company. The company was formed in 2026 when it was spun off from Corteva. Vylor is a leader in the development of genetically modified seeds and other advanced germplasm and traits that boost crop yields. The company operates in two segments based on geography—Americas and Rest of World. The Americas segment, which includes North and South America, generates most sales and profits.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: